2.50
Hdl Handle:
http://hdl.handle.net/2336/2046
Title:
Kostnaðarhagkvæmnisgreining á bólusetningu gegn meningókokkum C á Íslandi
Other Titles:
Cost-effectiveness analysis on meningococcal serogroup C vaccination
Authors:
Guðmundur I. Bergþórsson; Þórólfur Matthíasson; Þórólfur Guðnason; Haraldur Briem
Citation:
Læknablaðið 2004;90(5):379-83
Issue Date:
1-May-2004
Abstract:
Meningococci C are bacteria that can cause meningitis and severe bacteremia. In Iceland 8-15 cases of meningococcal disease can be expected annually. The case fatality ratio is approximately 10%. After the approval of the Icelandic government The State Epidemiologist started a vaccination campaign for all individuals from 6 months to 19 years of age in the country. The purpose of this investigation is to evaluate the cost effectiveness of the vaccination programme. The cost effectiveness is made from the viewpoint of the Icelandic state. The cost per year saved is used as a marker for success. The cost effectiveness analysis reveals that the cost per case avoided is 618.000 Icelandic kronas and the cost per life year saved is 101.000 Icelandic kronas. In comparison the cost per case avoided is 2.481.334 Icelandic kronas and the cost per life saved is 857.483 Icelandic kronas in England and Wales. We conclude that vaccination against meningococci C is very cost effective but lower cost in Iceland can mainly be explained by lower cost of distributing and administering the vaccine to the vaccinees in Iceland compared to England and Wales.
Description:
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Open
Additional Links:
http://www.laeknabladid.is

Full metadata record

DC FieldValue Language
dc.contributor.authorGuðmundur I. Bergþórsson-
dc.contributor.authorÞórólfur Matthíasson-
dc.contributor.authorÞórólfur Guðnason-
dc.contributor.authorHaraldur Briemen
dc.date.accessioned2006-04-28T14:59:13Z-
dc.date.available2006-04-28T14:59:13Z-
dc.date.issued2004-05-01T14:59:13Z-
dc.identifier.citationLæknablaðið 2004;90(5):379-83en
dc.identifier.issn0023-7213-
dc.identifier.pmid16819032-
dc.identifier.urihttp://hdl.handle.net/2336/2046-
dc.descriptionNeðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Openen
dc.description.abstractMeningococci C are bacteria that can cause meningitis and severe bacteremia. In Iceland 8-15 cases of meningococcal disease can be expected annually. The case fatality ratio is approximately 10%. After the approval of the Icelandic government The State Epidemiologist started a vaccination campaign for all individuals from 6 months to 19 years of age in the country. The purpose of this investigation is to evaluate the cost effectiveness of the vaccination programme. The cost effectiveness is made from the viewpoint of the Icelandic state. The cost per year saved is used as a marker for success. The cost effectiveness analysis reveals that the cost per case avoided is 618.000 Icelandic kronas and the cost per life year saved is 101.000 Icelandic kronas. In comparison the cost per case avoided is 2.481.334 Icelandic kronas and the cost per life saved is 857.483 Icelandic kronas in England and Wales. We conclude that vaccination against meningococci C is very cost effective but lower cost in Iceland can mainly be explained by lower cost of distributing and administering the vaccine to the vaccinees in Iceland compared to England and Wales.en
dc.language.isoisen
dc.publisherLæknafélag Íslands, Læknafélag Reykjavíkuren
dc.relation.urlhttp://www.laeknabladid.isen
dc.subjectMeningókokkar Cen
dc.subjectÓnæmisaðgerðiren
dc.subjectBólusetningaren
dc.subjectHeilahimnubólgaen
dc.subjectHeilsuhagfræðien
dc.subject.classificationLBL12en
dc.subject.classificationFræðigreinaren
dc.subject.meshMeningococcal Diseaseen
dc.subject.meshCost-effectiveness analysisen
dc.titleKostnaðarhagkvæmnisgreining á bólusetningu gegn meningókokkum C á Íslandien
dc.title.alternativeCost-effectiveness analysis on meningococcal serogroup C vaccinationen
dc.typeArticleen
dc.identifier.journalLæknablaðiðis
dc.format.digYES-

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.